NASDAQ:URGN - Urogen Pharma Stock Price, Forecast & News

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Urogen Pharma Ltd (NASDAQ:URGN) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.26) by $0.20. View Urogen Pharma's Earnings History.

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Urogen Pharma.

8 Wall Street analysts have issued 1 year price targets for Urogen Pharma's stock. Their forecasts range from $37.00 to $75.00. On average, they anticipate Urogen Pharma's share price to reach $50.14 in the next twelve months. This suggests a possible upside of 65.6% from the stock's current price. View Analyst Price Targets for Urogen Pharma.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.

Press coverage about URGN stock has trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Urogen Pharma earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Urogen Pharma.

Urogen Pharma saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,120,000 shares, an increase of 17.8% from the January 15th total of 1,800,000 shares. Based on an average trading volume of 179,400 shares, the short-interest ratio is currently 11.8 days. Currently, 12.5% of the company's stock are sold short. View Urogen Pharma's Current Options Chain.

Some companies that are related to Urogen Pharma include ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Ra Pharmaceuticals (RARX), Synthorx (THOR), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Forty Seven (FTSV), Xencor (XNCR), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX) and Cambrex (CBM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Urogen Pharma investors own include Kite Pharma (KITE), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Nektar Therapeutics (NKTR), Neurocrine Biosciences (NBIX), AbbVie (ABBV), Crispr Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Immunomedics (IMMU) and Puma Biotechnology (PBYI).

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Urogen Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Wildcat Capital Management LLC (5.53%), Phoenix Holdings Ltd. (3.99%), Migdal Insurance & Financial Holdings Ltd. (3.53%), Credit Suisse AG (3.20%), State Street Corp (1.97%) and FMR LLC (1.51%). Company insiders that own Urogen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Institutional Ownership Trends for Urogen Pharma.

URGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Migdal Insurance & Financial Holdings Ltd., Goldman Sachs Group Inc., Bank Hapoalim BM, Private Advisors LLC, New York State Common Retirement Fund, Victory Capital Management Inc. and Quantbot Technologies LP. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Insider Buying and Selling for Urogen Pharma.

URGN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Phoenix Holdings Ltd., Wildcat Capital Management LLC, Jane Street Group LLC, Credit Suisse AG, State Street Corp, Meitav Dash Investments Ltd. and California Public Employees Retirement System. Company insiders that have bought Urogen Pharma stock in the last two years include Elizabeth A Barrett and Mark Schoenberg. View Insider Buying and Selling for Urogen Pharma.

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of URGN stock can currently be purchased for approximately $30.28.

Urogen Pharma has a market capitalization of $632.85 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.View Additional Information About Urogen Pharma.

The official website for Urogen Pharma is http://www.urogen.com/.

Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]